You're contacting media contact of this press release

Title: Retatrutide Clinical Trial Results Highlight Growing Interest in Next-Generation Peptide Research, Says Platinum BioLabs

United States, 31st Oct 2026 – New clinical trial findings involving retatrutide are drawing attention across the pharmaceutical and metabolic research sectors after the investigational compound demonstrated significantly greater average weight reduction than semaglutide (Ozempic 2 mg) in a Phase 3 study involving adults with Type 2 diabetes.Platinum BioLabs, a U.S.-based research chemical supplier specializing in peptides and chemical compounds for laboratory, analytical, and research applications, recognizes the findings as an important development in ongoing research into next-generation peptide compounds and metabolic pathways.The results, announced by Eli Lilly on October 28, 2026, provide further insight into retatrutide's potential and the growing scientific interest in compounds that interact with multiple hormone receptors.Phase 3 Findings Demonstrate Significant Weight ReductionThe TRANSCEND-T2D-2 clinical trial evaluated retatrutide against semaglutide 2 mg over an 80-week treatment period in adults with Type 2 diabetes.According to the reported findings, participants receiving the 9 mg retatrutide dose experienced an average body-weight reduction of 19.5%, while those receiving the 12 mg dose experienced an average reduction of 20.9%.By comparison, participants receiving semaglutide 2 mg experienced an average weight reduction of 9.4%.The results represent more than twice the average weight reduction observed in the semaglutide comparison group at the higher retatrutide dose.The study also evaluated glycemic control, with retatrutide demonstrating an average A1C reduction of 2.2 percentage points compared with 1.8 percentage points for semaglutide.These findings are specific to the trial population and treatment conditions. They should not be interpreted as...

This press release is issued by King Newswire